---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-015018"
form_type: "8-K"
ticker: "URGN"
cik: "0001668243"
company_name: "UroGen Pharma Ltd."
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T22:47:20.960830+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# UroGen Q1 2026: ZUSDURI revenue $29.2M (+109% QoQ); net loss narrows to $0.47/share

## Summary
- Total revenue $51.0M, up 152% YoY on ZUSDURI launch and JELMYTO growth.
- ZUSDURI net revenue $29.2M, 109% sequential growth; 256 unique prescribers as of March 31.
- JELMYTO revenue $21.7M (+7% YoY); FY 2026 guidance reaffirmed at $97–101M.
- Net loss $23.6M ($0.47/share) vs $43.8M ($0.92/share) in Q1 2025; cash $140.3M.
- UGN-103 NDA submission on track for H2 2026; six-month durability data expected mid-2026.

## SEC filing metadata
- accession: 0001437749-26-015018
- form_type: 8-K
- ticker: URGN
- cik: 0001668243
- company_name: UroGen Pharma Ltd.
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1668243/000143774926015018/0001437749-26-015018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1668243/000143774926015018/urgn20260504_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-015018
- JSON: https://secwatch.observer/filing/0001437749-26-015018.json
- Plain text: https://secwatch.observer/filing/0001437749-26-015018.txt

## Source-grounded claims
- claim_id: 0f27c57fe6a27f41bfa2ca1ca9b7635f0330f38d
  claim: UroGen Pharma Ltd. reported the first quarter ended March 31, 2026 results: revenue ZUSDURI™ generated revenue of $29.2 million in Q1 2026.
  evidence_excerpt: On May 6, 2026, UroGen Pharma Ltd. (the “Company”) announced its financial results for the quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1668243/000143774926015018/0001437749-26-015018-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.